HOW CAN WE HELP YOU? Call 1-800-TRY-CHOP
CCCR Research Studies

1 - 38 of 38
22LL011; Epcoritamab in B-cell Neoplasms

CHOP in collaboration with AbbVie, is conducting a study for pediatric patients from 1 year of age to 25 years of age with relapsed or refractory aggressive mature B-cell neoplasms (including diffuse large B-cell lymphoma, Burkitt and Burkitt-like lymphoma/leukemia).
AALL2121: SNDX-5613 for Relapsed or Refractory Leukemia

This study enrolls patients that have been diagnosed with acute leukemia associated with a KMT2A (MLL) gene rearrangement (referred to as KMT2Arearranged, or KMT2A-R).
AAML1921; Bosutinib for Chronic Myeloid Leukemia
The overall goals of this study are to find the best dose of bosutinib that we can give safely, and to find out what effects, good and/or bad, bosutinib has on children and adolescents with Chronic Myeloid Leukemia (CML).
ABA3 GVHD ProRx post Allo HACT

Afamitresgene Autoleucel in Pediatric Subjects with MAGE-A4 Positive Tumors

This study involves an investigational cellular therapy called Afamitresgene Autoleucel.
Alpelisib in PIK3CA Associated Lymphatic Malformations
This study has several parts and involves taking a study drug called alpelisib.Alpelisib in PIK3CA-related overgrowth syndrome
The purpose of this study is to find out if alpelisib (BYL719; the “study drug”), is safe and effective (can help) people who have PIK3CA-related overgrowth spectrum (PROS) disease.
BA3011 for advanced solid tumors

This study involves taking a study drug called BA3011. The overall goal of this study is to see if BA3011 is a possible treatment for patients with sarcoma.
Cabo/Ifos in Ewing Sarcoma and Osteosarcoma (CaIRS trial)

This study enrolls patients between 5 and 40 years of age with a diagnosis of Ewing sarcoma (including Ewing-like sarcoma) or osteosarcoma that has progressed on or relapsed after upfront initial therapy.
Cancer Genomic Testing Study
The Department of Genomic Diagnostics is interested in studying genetic/molecular testing results from patients who are diagnosed with cancer as confirmed by genetic testing done at CHOP.
Carfilzomib in ALL
This clinical trial is adding the study drug, Carfilzomib, to a standard relapse chemotherapy regimen.
Chemotherapy-induced Nausea and Vomiting Control
The overall goal of this study is to find the best strategies used by parents and patients for managing these symptoms when receiving maintenance therapy.
Copanlisib in Solid Tumors or Lymphoma
The purpose of this study is to find out what is the right dose of copanlisib in children and adolescents, and if your disease responds to this new drug.
Fludarabine/Cytarabine/Gemtuzumab Ozogamicin With or Without Venetoclax in Relapsed AML

This study involves taking a study drug called venetoclax with or without standard of care chemotherapy.
GD2CART for Osteosarcoma or Neuroblastoma
This study enrolls patients that have been diagnosed with osteosarcoma or neuroblastoma that has come back (relapsed) or has not responded to standard treatments (refractory).Humanized CART19 Phase 2 Trial

This purpose of this study is to determine the efficacy of humanized CD19 CAR T cells (huCART19) in pediatric and young adult patients with high-risk relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).
INBRX-109 in Ewing Sarcoma and Gastrointestinal Stromal Tumor (GIST)
This study involves taking a study drug called INBRX-109.
Larotrectinib RAI Thyroid (LANTERN)
This study enrolls patients with newly diagnosed differentiated thyroid cancer (papillary thyroid cancer or follicular thyroid cancer) that has spread to the lungs and has a genetic mutation called and NTRK fusion.
Lurbinectedin in Ewing Sarcoma

This study involves taking a study drug called lurbinectedin. The overall goal of this study is to see if different doses of lurbinectedin are safe and effective at treating children and young adults with recurrent or relapsed solid tumors, including Ewing Sarcoma.
Lutathera in Somatostatin Neuroendocrine Tumors

This study involves taking a study drug called Lutathera.
NEPENTHE - Next Generation Personalized Neuroblastoma Therapy

This is a clinical trial for patients with neuroblastoma that has returned (relapsed) or has not responded to standard treatment.
ON-TRK

The goal of this observational study is to describe the safety and effectiveness of larotrectinib in patients with locally advanced or metastatic TRK fusion cancer for whom a decision to treat with larotrectinib has been made before enrollment.
Oral Asciminib in CML
This study involves taking a study drug called asciminib.
Palbociclib, Irinotecan, and Temozolomide in Ewing Sarcoma

The purpose of the Phase 2 portion of this study is to evaluate the safety and efficacy of the study drug called palbociclib when given in combination with two other drugs (temozolomide and irinotecan) in patients with Ewing sarcoma and when given in combination with topotecan and cyclophosphamide in patients with neuroblastoma.
PTX-022 in the Treatment of Microcystic Lymphatic Malformations
The purpose of this study is to see if a new investigational topical (applied to the skin) formulation of sirolimus, PTX-022 (the study drug), is safe and effective in treating participants with microcystic Lymphatic Malformations.
Repotrectinib for ALK, ROS1, or NTRK1-3 Alterations

The purpose of this study is to test the safety and efficacy of the investigational drug called repotrectinib in children whose cancers have specific genetic changes (in the ALK, ROS1, or NTRK1-3 genes).
Selpercatinib in Solid or CNS tumors with RET-Alterations

The purpose of this study is to test the safety and efficacy of the investigational drug called Selpercatinib in children whose cancers have a specific genetic change (RET-fusion or RET-mutation).
Selpercatinib in Thyroid Cancer (Collaboration with the International Thyroid Oncology Group)

This study involves taking a study drug called selpercatinib.
Selpercatinib RAI Thyroid (RAISE Trial)
Synovial Sarcoma Registry / Biospecimen Repository

The purpose of this study is to establish a registry and biorepository for synovial sarcoma patients by collecting and storing data and biospecimens, such as blood, saliva and/or buccal (cheek) swabs, and tumor tissue.
TAPISTRY

The purpose of this study is to evaluate the effects, good or bad, of targeted therapies or immunotherapy (drugs that help the body's immune system fight cancer cells) in patients who have solid tumors with specific genetic alterations or with a high number of mutations.
Tara-002 in Lymphatic Malformations

This study is for people with growing abnormal lymph vessels called lymphatic malformations (LMs).
TAS-117 in Tumors Harboring Germline PTEN Inactivating Mutations
Study is to see if TAS-117 is a possible treatment for advanced cancers with germline mutations in the PTEN gene.
Tegavivint for the Treatment of Solid Tumors, Lymphomas & Desmoids

This study involves taking a study drug called tegavivint. The study will be testing different doses of the study drug to find the safest dose.
The LiFFT Study

This study involves taking a study drug called lurbinectedin.
Tiragolumab and Atezolizumab in SMARCB1 or SMARCA4 Deficient Tumors

This study enrolls patients that have been diagnosed with SMARCB1 or SMARCB4 deficient cancer that has either come back (“relapsed”) or does not respond to therapy (“is refractory”) or have been newly diagnosed with a SMARCB1 or SMARCB4 deficient cancer that has no known standard treatment.
Uproleselan in Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) or Mixed Phenotype Acute Leukemia (MPAL)

This study enrolls patients that have been diagnosed with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or mixed phenotype acute leukemia (MPAL) that has either come back (‘relapsed’) or does not respond to therapy (‘refractory’).